id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2014-D-0234-0029,FDA,FDA-2014-D-0234,Clinical Pharmacology Data To Support a Demonstration of Biosimilarity to a Reference Product; Guidance for Industry; Availability,Notice,Notice of Availability,2016-12-29T05:00:00Z,2016,12,2016-12-29T05:00:00Z,,2016-12-29T14:18:33Z,2016-31511,0,0,090000648243d24e
FDA-2014-D-0234-0030,FDA,FDA-2014-D-0234,Clinical Pharmacology Data to Support a Demonstration of Biosimilarity to a Reference Product Guidance for Industry,Other,Guidance,2016-12-29T05:00:00Z,2016,12,2016-12-29T05:00:00Z,,2024-11-12T06:15:55Z,,1,0,090000648243d98f
FDA-2014-D-0234-0002,FDA,FDA-2014-D-0234,Draft Guidance for Industry on Clinical Pharmacology Data to Support a Demonstration of Biosimilarity to a Reference Product,Other,Guidance,2014-05-14T04:00:00Z,2014,5,2014-05-14T04:00:00Z,,2019-06-18T16:43:26Z,,0,0,09000064816f8cdc
FDA-2014-D-0234-0001,FDA,FDA-2014-D-0234,"Draft Guidance for Industry on Clinical Pharmacology Data To Support a
Demonstration of Biosimilarity to a Reference Product; Availability",Notice,Notice of Availability,2014-05-14T04:00:00Z,2014,5,2014-05-14T04:00:00Z,2014-08-13T03:59:59Z,2014-08-15T01:04:06Z,2014-11053,0,0,09000064816f9410